Remarks

I. Status of the Claims

Upon entry of the foregoing amendment, claims 86-162 are pending in the application, with claims 86 and 87 being the independent claims. Claims 1-85 have been canceled and new claims 86-162 have been added. These changes are believed to introduce no new matter, and their entry is respectfully requested.

II. The Amendments

The new claims are directed to methods for producing a recombinant antibody having increased Fc mediated cellular cytotoxicity (claim 86) or, alternatively, increased Fc receptor binding affinity (claim 87). In addition, the new claims are directed to the use of such antibodies for lysing target cells (claim 133).

Support for the new claims can be found inter alia in the disclosure as follows:

CLAIM	SUPPORT
86	See, for example, page 2, lines 29-31; page 22, line 33, through page 23, line 3; page 7, lines 21-27; page 8, lines 13-19, and line 26 through page 9, line 4; and claim 74 as originally filed
87	See, for example, page 21, lines 15-25; and page 24, lines 3-8.
88	See, for example, page 37, line 31, through page 38, line 6.
89	See, for example, page 37, line 31, through page 38, line 6; FIG. 9E.
90-101	See, for example, page 7, lines 17-20; page 15, line 33, through page 16, line 8; page 38, lines 2-6; and claims 6-7 and 55 as filed.
102-105	See, for example, page 12, line 32, through page 13, line 1; and page 13, lines 18-30.

106-107	See, for example, page 13, lines 14-17.
109 100	See for any new 27 line 21 through page 29 line 6; and FIG
108-109	See, for example, page 37, line 31, through page 38, line 6; and FIG.
	9E.
110-113	See, for example, page 7, lines 14-16; page 23, lines 12-26.
114-119	See, for example, page 37, line 22, through page 38, line 14: FIG. 9.
120-124	See, for example, page 1, lines 13-16; page 3, lines 9-12; page 8, lines 13-16; page 9, lines 5-14; page 23, lines 12-26.
125-128	See, for example, page 37, line 22, through page 38, line 6; FIG. 9
129	See, for example, page 37, lines 19-21.
130	See, for example, page 22, line 33, through page 23, line 11.
131-132	See, for example, page 26, lines 1-23.
133-156	See, Examples 3 and 4; specifically, page 37, line 23, through page
	39, line 33; and page 42, line 8, through page 43, line 22.
157-158	See, for example, page 26, lines 1-23.
159	See, for example, page 7, lines 21-27.
160-162	See, for example, page 20, line 30, through page 21, line 14.

Accordingly, no new matter is believed to have been added by the amendments, and their entry is respectfully requested.

Conclusion

Prompt and favorable consideration of this Preliminary Amendment is respectfully requested. Applicants believe the present application is in condition for allowance. If the Examiner believes, for any reason, that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided.

Respectfully submitted,

STERNE, KESSLER, GOLDSZEIN & FOX P.L.L.C.

Timothy J. Splea, Jr. Attorney for Applicants

Registration No. 41,306

Date: November 1, 2005

1100 New York Avenue, N.W. Washington, D.C. 20005-3934

(202) 371-2600